Biopharmaceutical company Liquidia Corp. (LQDA) reported Wednesday that its fiscal 2024 net loss was $130.4 million or $1.66 per share, compared to a net loss of $78.5 million or $1.21 per share a year ago.
Loss from operations widened to $121.29 million from prior year's loss of $73.38 million.
Revenue was $14.0 million for the year, lower than last year's $17.5 million.
Revenue related primarily to the promotion agreement with Sandoz, Inc. The decrease of $3.5 million was primarily due to lower sales quantities, driven by limitations on the availability of pumps used to administer Treprostinil Injection subcutaneously.
The company said sales quantities will continue to be impacted until alternative pumps are available.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.